# A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

> **NCT06535412** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.** · enrollment: 218 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** IMC-002 + SOC
- **DRUG:** Placebo + SOC

## Key facts

- **NCT ID:** NCT06535412
- **Lead sponsor:** ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2025-12-10
- **Final completion:** 2026-06-10
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06535412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06535412, "A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06535412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*